Prelude Capital Management’s Novo Nordisk NVO Stock Holding History

Prelude Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.9K	Buy	+15,300	New	+$657K	﹤0.01%	1183
2025 Q1	–	Sell	-3,300	Closed	-$284K	–	1432
2024 Q4	$284K	Buy	+3,300	New	+$357K	0.02%	823
2021 Q3	–	Sell	-1,200	Closed	-$315K	–	1938
2021 Q2	$315K	Buy	+1,200	New	+$46.5K	0.01%	1172

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Prelude Capital Management's NVO Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,816 shares worth $231K. The stake represents 0.02% of the portfolio and ranks #920 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in NVO as recently as Q2 2025.

Prelude Capital Management first reported a position in NVO in Q2 2013 and has held it in 26 quarters since. The position peaked at $1.61M in Q1 2023. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Prelude Capital Management held 4,816 shares of Novo Nordisk worth $231K as of Q2 2026.
Novo Nordisk was a new Prelude Capital Management position in Q2 2026.
Novo Nordisk made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #920 holding.
Prelude Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 26 quarters since.
Prelude Capital Management's Novo Nordisk position peaked at $1.61M in Q1 2023.
1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.